Safety of long-acting β2-agonists in asthma.
Louise
L
Rishton
D005260:Female; D006801:Humans; D008297:Male; D000280:Administration, Inhalation; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality; D019819:Budesonide / Q000008:administration & dosage / Q000009:adverse effects; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000009:adverse effects; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D000068759:Formoterol Fumarate / Q000008:administration & dosage / Q000009:adverse effects; D061214:Patient Safety; D018570:Risk Assessment; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
D019819:Budesonide; D003692:Delayed-Action Preparations; D000068759:Formoterol Fumarate